Financing, Equity Capital Markets

ImmunoVaccine (IMV, Inc.)

10/20
|
$50.0 Million
Piper Sandler served as bookrunner for Immovaccine on an ATM offering
Sub-Type
At the Market Offering
Sub-Sector
Biopharma